Panduratin A (1), a cyclohexenyl chalcone isolated from Boesenbergia rotunda, has been reported to exhibit various biological activities, including antitumor effects. However, its antiproliferative activity against glioblastoma cells and glioblastoma-derived cancer stem-like cells (CSCs), and the molecular basis of this activity, remain incompletely elucidated. In this study, we evaluated the antiproliferative activity of 1 against U-251 MG glioblastoma cells (non-CSCs) and U-251 MG CSCs and found that 1 exhibited potent activity against both cell populations. To investigate the structural features associated with this activity, cyclohexenyl chalcone derivatives of 1 (2-11) were synthesized through a chalcone intermediate generated from an acetophenone precursor, followed by Diels-Alder reactions with dienes. Structure-activity relationship analysis, particularly in U-251 MG non-CSCs, suggested that the phenolic oxygen functionalities of 1 contribute to its potent activity, whereas some acetylated derivatives retained moderate activity. Based on this observation, affinity-based target identification using U-251 MG non-CSC extracts identified prohibitin 2 (PHB2), an inner mitochondrial membrane protein, as a candidate binding protein for 1. In these cells, 1 also markedly altered the mitochondrial morphology and reduced the mitochondrial membrane potential. Together, these findings suggest that the antiproliferative activity of 1 in U-251 MG glioblastoma cells may be associated with PHB2 and mitochondrial alterations.
No takes yet. Share an insight, caveat, or question.
Araki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: